Literature DB >> 22271713

Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis.

Pasquale Santangeli1, Luigi Di Biase, Rodney Horton, J David Burkhardt, Javier Sanchez, Amin Al-Ahmad, Richard Hongo, Salwa Beheiry, Rong Bai, Prasant Mohanty, William R Lewis, Andrea Natale.   

Abstract

BACKGROUND: Observational data suggest that performing radiofrequency catheter ablation of atrial fibrillation (AF) under therapeutic warfarin (continuous warfarin [CW]) may reduce the periprocedural risk of complications, such as thromboembolic events, compared to warfarin discontinuation (DW) with periprocedural bridging with heparin. We systematically reviewed the available evidence on the impact of CW compared with DW on periprocedural complications of AF catheter ablation. METHODS AND
RESULTS: We searched major Web databases for studies on radiofrequency catheter ablation of AF under CW versus DW with periprocedural bridging with heparin. Data on periprocedural complications were extracted. We identified 9 studies (1 large case series indirectly compared with the latest Worldwide Survey). A total of 27,402 patients were included in the analysis (6400 undergoing ablation with CW). CW was associated with a striking decrease of thromboembolic complications (OR, 0.10; 95% CI, 0.05-0.23; P<0.001) and minor bleeding complications (OR, 0.38; 95% CI, 0.21-0.71; P=0.002) compared with DW. CW also did not increase the risk of major bleeding (OR, 0.67; 95% CI, 0.31-1.43; P=0.30), including cardiac tamponade (OR, 0.69; 95% CI, 0.19-2.47; P=0.57).
CONCLUSIONS: There is highly consistent evidence from observational studies that a CW strategy during radiofrequency catheter ablation of AF reduces the risk of thromboembolic complications without increasing the risk of bleeding.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22271713     DOI: 10.1161/CIRCEP.111.964916

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  50 in total

1.  Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation.

Authors:  Melanie Gunawardene; S Willems; B Schäffer; J Moser; R Ö Akbulak; M Jularic; C Eickholt; J Nührich; C Meyer; P Kuklik; S Sehner; V Czerner; B A Hoffmann
Journal:  Clin Res Cardiol       Date:  2016-07-19       Impact factor: 5.460

2.  Periprocedural dabigatran anticoagulation for atrial fibrillation ablation: do we have enough information to make a rational decision.

Authors:  Amit Noheria; Samuel J Asirvatham
Journal:  J Interv Card Electrophysiol       Date:  2013-07-28       Impact factor: 1.900

3.  2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.

Authors:  Hugh Calkins; Gerhard Hindricks; Riccardo Cappato; Young-Hoon Kim; Eduardo B Saad; Luis Aguinaga; Joseph G Akar; Vinay Badhwar; Josep Brugada; John Camm; Peng-Sheng Chen; Shih-Ann Chen; Mina K Chung; Jens Cosedis Nielsen; Anne B Curtis; D Wyn Davies; John D Day; André d'Avila; N M S Natasja de Groot; Luigi Di Biase; Mattias Duytschaever; James R Edgerton; Kenneth A Ellenbogen; Patrick T Ellinor; Sabine Ernst; Guilherme Fenelon; Edward P Gerstenfeld; David E Haines; Michel Haissaguerre; Robert H Helm; Elaine Hylek; Warren M Jackman; Jose Jalife; Jonathan M Kalman; Josef Kautzner; Hans Kottkamp; Karl Heinz Kuck; Koichiro Kumagai; Richard Lee; Thorsten Lewalter; Bruce D Lindsay; Laurent Macle; Moussa Mansour; Francis E Marchlinski; Gregory F Michaud; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Ken Okumura; Douglas Packer; Evgeny Pokushalov; Matthew R Reynolds; Prashanthan Sanders; Mauricio Scanavacca; Richard Schilling; Claudio Tondo; Hsuan-Ming Tsao; Atul Verma; David J Wilber; Teiichi Yamane
Journal:  Heart Rhythm       Date:  2017-05-12       Impact factor: 6.343

Review 4.  New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a meta-analysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted or continuous warfarin.

Authors:  Yue Zhao; Yuan Yang; Xuejiao Tang; Xiang Yu; Lei Zhang; Hua Xiao
Journal:  J Interv Card Electrophysiol       Date:  2017-01-12       Impact factor: 1.900

5.  2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society.

Authors:  Hugh Calkins; Karl Heinz Kuck; Riccardo Cappato; Josep Brugada; A John Camm; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; John DiMarco; James Edgerton; Kenneth Ellenbogen; Michael D Ezekowitz; David E Haines; Michel Haissaguerre; Gerhard Hindricks; Yoshito Iesaka; Warren Jackman; José Jalife; Pierre Jais; Jonathan Kalman; David Keane; Young-Hoon Kim; Paulus Kirchhof; George Klein; Hans Kottkamp; Koichiro Kumagai; Bruce D Lindsay; Moussa Mansour; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Douglas L Packer; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Vivek Reddy; Jeremy N Ruskin; Richard J Shemin; Hsuan-Ming Tsao; David Wilber
Journal:  Heart Rhythm       Date:  2012-03-01       Impact factor: 6.343

6.  Complications from catheter ablation of atrial fibrillation: impact of current and emerging ablation technologies.

Authors:  Nikhil C Panda; Jim W Cheung
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-10

7.  Safety and efficacy of DOACs vs acenocoumarol in patients undergoing catheter ablation of atrial fibrillation.

Authors:  Konstantinos Vlachos; Michael Efremidis; George Bazoukis; Konstantinos P Letsas; Athanasios Saplaouras; Stamatis Georgopoulos; Nikolaos Karamichalakis; Aikaterini Rokiza; Antigoni Sakellaropoulou; Angelos Michail Kolokathis; Theodoros Efremidis; Dimitrios Asvestas; Antonios Sideris
Journal:  Clin Cardiol       Date:  2017-05-31       Impact factor: 2.882

8.  [Catheter ablation of paroxysmal atrial fibrillation. Optimal approach and result].

Authors:  Shibu Mathew; Andreas Metzner; Feifan Ouyang; Karl-Heinz Kuck; Roland Richard Tilz
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-04-16

Review 9.  Clinical considerations of anticoagulation therapy for patients with atrial fibrillation.

Authors:  Shu Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2012-08       Impact factor: 3.066

10.  Metabolic benefits of rivaroxaban in non-valvular atrial fibrillation patients after radiofrequency catheter ablation.

Authors:  Jun Zhu; Rong-Jun Gao; Qiang Liu; Ru-Hong Jiang; Lu Yu; Ya-Xun Sun; Pei Zhang; Jian-Wei Lin; Yang Ye; Zu-Wen Zhang; Shi-Quan Chen; Hui Cheng; Xia Sheng; Chen-Yang Jiang
Journal:  J Zhejiang Univ Sci B       Date:  2017 Nov.       Impact factor: 3.066

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.